Concord Biotech Ltd

Concord Biotech Ltd Share Price Today: Live Updates & Key Insights

Get insights on Concord Biotech Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Concord Biotech Ltd Share Price Chart

Concord Biotech Ltd Fundamentals

Traded Volume: 36,418

Market Cap(Cr): 14,936

Avg Traded Price 1429.88

1 Year return -28.30%

Upper Circuit 1,452.4

Lower Circuit 1,415

P/E TTM 46.00

P/B Ratio 31.00

Traded Value(Cr) 519.94

EPS TTM 30.965

Book value 30.965

Dividend 1.00%

Concord Biotech Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Concord Biotech Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Concord Biotech Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -2.13%

1M -4.61%

3M -15.69%

1Y -28.30%

YTD -32.97%

Concord Biotech Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Concord Biotech Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 47660.00

Day Before Yesterday 3.47L

1W Avg 1.39L

1M Avg 98387.62

3M Avg 1.07L

Concord Biotech Ltd Technical Details

Concord Biotech Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 1411

Support 2 1394

Support 3 1374

Pivot Point : 1432

Resistance 1 1448

Resistance 2 1469

Resistance 3 1486

Concord Biotech Ltd Corporate Actions

Concord Biotech Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Concord Biotech Ltd’s capital allocation strategies.

All

Ex-Date 03-Sep-2025 Type D Description 10.70/share@1070.00% Record Date 03-Sep-2025 Ratio 1070.00

Ex-Date 21-Jun-2024 Type D Description 8.75/share@875.00% Record Date 22-Jun-2024 Ratio 875.00

Dividends

Announcement Date 03-Sep-2025 Ex Dividend Date 03-Sep-2025 Dividend(%) 1070

Announcement Date 21-Jun-2024 Ex Dividend Date 21-Jun-2024 Dividend(%) 875

Bonus

No Bonus has been declared by CONCORDBIO

Splits

No Split has been declared by CONCORDBIO

Others

Rights No Rights has been declared by CONCORDBIO

Concord Biotech Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Concord Biotech Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Concord Biotech Ltd's relative performance and valuation against major competitors.

Stock Name Biocon Ltd ₹396.85 (+0.43%) M. Cap (Cr) 530.57 1 Yr Return (%) +22.83% P/E (TTM) 109.28 PB Ratio 2.52

Stock Name Concord Biotech Ltd ₹1427.70 (-0.88%) M. Cap (Cr) 149.36 1 Yr Return (%) -28.30% P/E (TTM) 46.11 PB Ratio 8.24

Stock Name Advanced Enzyme Technologies Ltd ₹317.20 (-2.43%) M. Cap (Cr) 35.50 1 Yr Return (%) -14.48% P/E (TTM) 24.09 PB Ratio 2.65

Stock Name Panacea Biotec Ltd ₹345.15 (-3.21%) M. Cap (Cr) 21.14 1 Yr Return (%) -16.63% P/E (TTM) -292.00 PB Ratio 2.53

Stock Name Genesis IBRC India Ltd ₹158.30 (-1.98%) M. Cap (Cr) 2.06 1 Yr Return (%) NaN% P/E (TTM) -889.33 PB Ratio 24.12

Stock Name Alpa Laboratories Ltd ₹78.63 (-0.87%) M. Cap (Cr) 1.65 1 Yr Return (%) -28.91% P/E (TTM) 8.87 PB Ratio 0.97

Stock Name Bharat Immunological & Biological Corporation Ltd ₹20.20 (+0.40%) M. Cap (Cr) 0.87 1 Yr Return (%) -12.40% P/E (TTM) -4.72 PB Ratio 0.99

Concord Biotech Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Concord Biotech Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 244.52 Mar 2024 265.47 Mar 2023 246.00

PARTICULARS Investing Activities Mar 2025 -159.99 Mar 2024 -154.61 Mar 2023 -157.95

PARTICULARS Financing Activities Mar 2025 -98.77 Mar 2024 -99.21 Mar 2023 -85.22

PARTICULARS Net Cash Flow Mar 2025 -14.24 Mar 2024 11.64 Mar 2023 2.83

Concord Biotech Ltd Shareholding Pattern

This shows the ownership breakdown of Concord Biotech Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 44.08%

Public 38.32%

Other Institutions 5.02%

FII 8.03%

Mutual Funds 4.53%

About Concord Biotech Ltd

Concord Biotech Limited was originally incorporated as `Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to `Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC.The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat.In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020, Mycophenolate Sodium Tablets got launched in the US market.The Company introduced a new manufacturing unit at Limbasi, and commenced operations in July, 2021. As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. In August 2023, Company made an Initial Public Offer by issuing 20,925,652 Equity Shares aggregating to Rs 1551 Crores through Offer for Sale.The Company launched 21 new formulations products in 2025.

Chairman / Executive Director / M D / Promoter

SUDHIR JAIRAM VAID

Registered office 1482-86 Trasad Road, Dholka, Ahmedabad, Gujarat, 382225

FAX :91-079-68138700

Background

Incorporation Year 1984

Face Value ₹1.00

Market Lot 1

Concord Biotech Ltd Latest News

VIEW MORE NEWS

FAQs on Concord Biotech Ltd